Literature DB >> 18070848

Psychopathology in verified Huntington's disease gene carriers.

E van Duijn1, E M Kingma, R C van der Mast.   

Abstract

Huntington's disease is characterized by motor, cognitive, and neuropsychiatric symptoms. This study reviews original research on psychopathology in Huntington's disease that uses standardized instruments in verified gene carriers. Frequently reported neuropsychiatric symptoms are depressed mood, anxiety, irritability, and apathy, with prevalences of 33% to 76%. Obsessive-compulsive symptoms and psychosis occur less often with prevalences of 10% to 52% and 3% to 11%, respectively. Available research provides little insight into the true prevalences of psychopathology in Huntington's disease due to small sample sizes, use of different methodologies, and lack of comparison groups. Future research requires larger cohorts stratified to disease stage, consistent methodologies, and adequate comparison groups.

Entities:  

Mesh:

Year:  2007        PMID: 18070848     DOI: 10.1176/jnp.2007.19.4.441

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  74 in total

1.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 2.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

3.  Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data.

Authors:  Eric A Epping; Ji-In Kim; David Craufurd; Thomas M Brashers-Krug; Karen E Anderson; Elizabeth McCusker; Jolene Luther; Jeffrey D Long; Jane S Paulsen
Journal:  Am J Psychiatry       Date:  2015-10-16       Impact factor: 18.112

4.  Early Detection of Huntington Disease.

Authors:  Jane S Paulsen
Journal:  Future Neurol       Date:  2010-01

Review 5.  Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment.

Authors:  Thomas N Chase
Journal:  Neurotox Res       Date:  2010-05-15       Impact factor: 3.911

6.  Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Authors:  Noelle E Carlozzi; Siera Goodnight; Anna L Kratz; Julie C Stout; Michael K McCormack; Jane S Paulsen; Nicholas R Boileau; David Cella; Rebecca E Ready
Journal:  J Huntingtons Dis       Date:  2019

7.  Treatment of Apathy in Huntington's Disease and Other Movement Disorders.

Authors:  Ashok Krishnamoorthy; David Craufurd
Journal:  Curr Treat Options Neurol       Date:  2011-10       Impact factor: 3.598

8.  Depressive symptoms in prodromal Huntington's Disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex.

Authors:  Paul G Unschuld; Suresh E Joel; James J Pekar; Sarah A Reading; Kenichi Oishi; Julie McEntee; Megan Shanahan; Arnold Bakker; Russell L Margolis; Susan S Bassett; Adam Rosenblatt; Susumu Mori; Peter C van Zijl; Christopher A Ross; Graham W Redgrave
Journal:  Psychiatry Res       Date:  2012-09-11       Impact factor: 3.222

9.  Functional brain changes underlying irritability in premanifest Huntington's disease.

Authors:  Jan Van den Stock; François-Laurent De Winter; Rawaha Ahmad; Stefan Sunaert; Koen Van Laere; Wim Vandenberghe; Mathieu Vandenbulcke
Journal:  Hum Brain Mapp       Date:  2015-04-08       Impact factor: 5.038

Review 10.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.